24/7 Market News Snapshot 11 June, 2025 – Vaxart, Inc Common Stock (NASDAQ:VXRT)

June 11, 2025

DENVER, Colo., 11 June, 2025 (www.247marketnews.com) – (NASDAQ:VXRT) are discussed in this article.
Vaxart, Inc. (NASDAQ:VXRT) has experienced a significant surge in pre-market trading, reaching $0.700, which reflects an impressive increase of 78.16% from the previous close of $0.393. This remarkable activity is corroborated by a substantial trading volume of 17.89 million shares, reflecting heightened investor interest, possibly driven by the company’s recent advancements in oral vaccine technology.

In addition to this market momentum, Vaxart has announced encouraging topline results from a Phase 1 clinical trial focused on its second-generation norovirus vaccine constructs. Engaging 60 healthy volunteers, the trial indicated statistically significant increases in blocking antibodies against both GI.1 and GII.4 norovirus strains, achieving increases of 141% and 94%, respectively, in comparison to first-generation constructs.

These results affirm Vaxart’s commitment to pioneering oral recombinant pill vaccines, which leverage its proprietary delivery system. All assessed vaccine candidates demonstrated safety and tolerability across various dosage groups, with no serious adverse events linked to the vaccine.

Dr. Sean Tucker, Vaxart’s Founder and Chief Scientific Officer, expressed enthusiasm for the clinical findings, conveying confidence that the second-generation constructs will enhance immune responses and improve protection against infections. Vaxart’s innovative approach aims to boost antigen expression in the intestine, a critical factor for an effective immune response.

Looking forward, the company plans to initiate a Phase 2b study to further evaluate safety and immunogenicity, targeting a timeline for early commencement in the latter half of 2025. With no approved vaccine for norovirus currently available, which causes millions of infections annually and imposes significant economic burdens, Vaxart is poised to address this pressing healthcare need. The company is also seeking partnership opportunities to expedite the development of its promising vaccine candidates and intends to publish comprehensive trial findings in a peer-reviewed journal, ensuring stakeholders are updated on its progress.

Related news for (VXRT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.